

Forward-Looking Statements



Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business and projects; (iv) execution of the Company's vision and growth strategy and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.



Advancing molecules to medicines





Ibogaine is a lead molecule currently in use in unregulated settings



Noribogaine is a pharmacologically active metabolite of ibogaine

Next generation lead compounds include azepino-indoles and derivatives related to ibogaine

Ibogaine for the Treatment of Natures Addicting Alkaloids – Nicotine, Cocaine and Opium





The West African plant Tabernanthe iboga (Fam. Apocynaceae).

From Landrin "De l'iboga et de l'ibogaine" (1905)

Home News Governor Abbott Signs Ibogaine Treatment Research Law At Texas Capitol

Governor Abbott Signs Ibogaine Treatment Research Law At Texas Capitol

June 11, 2025 | Austin, Texas | Press Release

Governor Greg Abbott today signed <u>Senate Bill 2308</u> into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol.

"Texas is home to more veterans than any other state," said Governor Abbott. "Many of those veterans suffer from injuries both seen and unseen. A therapy that has shown great promise in treating those conditions is ibogaine. This law authorizes a Food and Drug Administration approved clinical drug trial that will seek approval of ibogaine as a medication for the treatment of opioid use disorder and other behavioral health conditions, especially those suffered by our veterans. Texas will now lead the way in America for the evaluation of ibogaine as a potential medication that can help improve the lives of so many veterans."



Organization

News

Ibogaine: Phase 1 Pharmacokinetic and Safety Trial



Investigational New Drug Application 39,680

August 25, 1993 (Ibogaine Veterans)



Dose
1 mg/kg

April 6, 1995 (Cocaine-Dependent Males)




Dose range
2, 4, 6 and 8 mg/kg


Landmark Phase I Clinical Trial at the University of Miami School of Medicine Abandoned Due to Lack of Funds

*Clinical trial progress delayed due to a lack of private or public funds

Discovery of Ibogaine's Primary Metabolite







Noribogaine has a long duration of action





Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence:

Clinical Observations and Treatment Outcomes

Deborah C. Mash, Linda Duque, Bryan Page and Kathleen Allen-Ferdinand


Department of Neurology, Leonard M. Miller School of Medicine, Miami, FL, United States, Department of Molecular and Cellular Pharmacology, Leonard M. Miller School of Medicine, Miami, FL, United States, Department of Anthropology, University of Miami, Coral Gables, FL, United States, General Medical Practice, Basseterre, Saint Kitts and Nevis


Published: 05 June 2018 doi: 10.3389/fphar.2018.00529



Novel Post Detoxification Treatments to Prevent Relapse to Opioid Use










Addiction Cravings: Symptoms, Treatment and Relapse Prevention



Reversing brain plasticity highjacked by alcohol and drugs

We identified noribogaine as an active metabolite of ibogaine.

We hypothesized that the rapid onset, potential therapeutic utility of ibogaine for substance use disorders, and the persistence of beneficial effects was mediated by noribogaine.

Today, other researchers have demonstrated that noribogaine is one of only a few molecules capable of promoting structural neural plasticity, a mechanism that is shared by **serotonergic psychedelics and ketamine**.



Noribogaine is a neuroplastogen therapy for the treatment of alcohol and opioid use disorders, and compulsive behavioral disorders.



DMX-1001 represents a groundbreaking therapeutic seeking to break the addictive cycle of AUD



DMX-1001 (oral noribogaine) employs polypharmacology and neuroplasticity for fast and lasting effect





First-in-Class neuroplastogen

Brings two circuit level mechanisms into one novel candidate for alcohol and other drug use disorders.



Affects multiple CNS targets

Engages multiple neurotransmitters within the addiction circuitry of the brain to reset chemical imbalances.



Potential to stimulate neuronal repair

Modulates
neuroplasticity to
enhance dopamine
pathways.
Supports recovery of

Supports recovery of brain regions affected by alcohol and drug misuse.




Favorable side effect profile


In clinical phase 1, noribogaine was safe and well tolerated.

Noribogaine has no euphoric effects or potential for abuse.

Animal models of alcoholism provide proof of concept which support DMX-1001 as a first-in-class AUD lead molecule







In clinical phase 1 and preclinical trials, noribogaine was well tolerated with no euphoric effects or potential for abuse.

Amir H. Rezvani, Ph.D., (unpublished data) *intraperitoneal injection

Noribogaine demonstrates proof of concept in Rodent Models of Substance Use Disorders



Model	Behavioral Effect	Reference
Naloxone-precipitated Withdrawal	Dose-dependent blockade in mice (30, 56, 100 mg/kg, p.o.)	Mash et al., 2016
Conditioned Place Preference	No rewarding effects (10, 30, 100 mg/kg, p.o.)	Mash et al., 2016
Noribogaine Self-administration	No rewarding effects (0.3, 1.0 mg/kg/infusion)	Schenk, unpublished study report
Discriminative Stimulus Effects	No kappa dysphoria No NMDA discriminative stimulus	Zubaran et al., 1999
Cocaine and Morphine Self-administration	Decrease (40 mg/kg, i.p.)	Glick et al., 1996
Nicotine Self-Administration	Dose-dependent decrease in rats (12.5, 25, 50 mg/kg p.o.)	Chang et al., 2015
Alcohol Operant Consumption	Decreased alcohol consumption in rats (intra VTA infusion, 10μM)	Carnicella et al. 2010

Alcohol use disorder is a major cause of harm



Prevalence, risks and consequence of alcohol use disorder (AUD)

Alcohol Use Disorder
People with AUD

29 million
United States

400 million
Worldwide

AUD Societal Cost Yearly in the U.S.

\$250 billion

Alcohol-Related Deaths

178,307Annual deaths (U.S.)

2.6 million

Annual deaths (Worldwide)

Emergency Department Visits

Yearly in the U.S.

4,126,082

All-alcohol related

STAT

By the numbers: America's alcoholrelated health problems are rising fast

By Isabella Cueto ♥ and J. Emory Parker ♥ June 27, 2024

And yet...

less than 6% of those affected by AUD in the U.S. receive medication.

Sources: 2023 NSDUH Tables 2.26A&B; 2021 HCUP-NEDS; 2020-2021 CDC ARDI; World Health Organization

*Acute and chronic alcohol-related deaths do not add to the total due to rounding. Alcohol misuse is also prevalent and impacts 2.3 billion individuals globally and contributes significantly to the disease burden. 1.34 billion people consumed harmful amounts of **alcohol** in 2020. Alcohol Use Disorder represents a substantial burden on EU healthcare systems and society as a whole.



DemeRx is a clinicalstage biotechnology company, based in Miami, developing next-generation addiction medicines with first-in-class profiles. **DemeRx is developing DMX-1001 (oral noribogaine)** for the treatment of Alcohol Use Disorder (AUD), a condition that affects 29 million people in the U.S.

DMX-1001 enhances neuroplasticity, allowing the brain to repair neural circuits damaged by chronic heavy drinking and potentially offering a more effective solution than existing pharmacological treatments for AUD.

DemeRx has completed a Phase 1b clinical trial to assess pharmacokinetics, pharmacodynamics and safety of DMX-1001 in 55 healthy volunteers, anticipating top-line data in Q3 2025.

This milestone will allow in DemeRx to initiate a Phase 2a trial in Q2'25 with 120 participants, aiming to validate the efficacy of an oral dose formulation.


DemeRx has secured an IP portfolio of 24 U.S. patents and 17 international patents, with 8 patent applications.

DemeRx's experienced leadership team includes pioneers in psychedelic medicine and addiction neurobiology, alongside seasoned biotech executives from prominent companies like Reckitt Benckiser Pharmaceuticals and Opiant Pharmaceuticals, the latter of which was acquired by Indivior for \$122 million.

DemeRx's pipeline in substance use disorders Our focus is on DMX-1001 in alcohol use disorder



Clinical and preclinical pipeline



DMX-1001 development roadmap: key milestones over the next 12 months



Phase 1: Single Ascending Dose (SAD)

- Objective: Assess safety and tolerability in healthy subjects
- **Dose regimen:** 3mg, 10mg, 30mg, 60mg and placebo (n = 60)
- Result: Safe, well-tolerated, with linear pharmacokinetics

Status: completed

Phase 1b: Multiple Ascending Dose (MAD)

- Objective: Evaluate safety and pharmacokinetics of repeat dosing
- Dose Regimen: 10mg, 20mg, 30mg, 40mg, and placebo, administered twice daily (n = 60)

Topline data expected: H1 2025

Phase 1b: Drug-Alcohol Interaction Study

- Objective: Investigate interaction between DMX-1001 and ethanol in social/moderate drinkers
- Dose regimen: Based on results from Phase 1b MAD trial

Planned Start: H2 2025

Phase 2: Safety & Efficacy Trial

- Objective: Evaluate safety and efficacy of DMX-1001 for alcohol use disorder
- Dose regimen: Target dose from Phase 1b MAD and drug-alcohol interaction trials

Planned Start: H1 2026

Pre-IND* Meeting

Meeting completed: H2 2023

Planned filing: H2 2025

IND

*Investigational New Drug Application (IND)

DemeRX has developed an extensive patent portfolio around DMX-1001



Patents provide protection across geographies

- The USPTO has granted 24 patents on these applications.
- An additional 17 patent grants and applications target the international market.
- DemeRx invested \$5.2 million to secure patents.

Company patents fall into four broad categories

- 01 Composition of matter
- O2 Combination therapies

Synthetic processes and formulations

04 Methods of use

Further eight patents currently under review

Our leadership team is highly experienced in addiction medicine and pharmaceutical development





Deborah C. Mash PhD

Chief Executive Officer and Founder

Mark Ellison PhD **Chief Development Officer**

E. Douglas Kramer MD

Vice President of Clinical and Regulatory Affairs

Highly regarded medical professional with a background in drug R&D, regulatory affairs and addiction treatment.

Seasoned CFO in the biotechnology and medical device industries, with a record of success in public and private companies.

John Thomas CPA

Chief Financial Officer

World-renowned expert in addiction treatment and the discovery and research of noribogaine for substance use disorders.

Proven record of driving startups and small pharma companies to successful product development and market launch.



































Significant market for improved AUD therapeutic treatment



Significant opportunity to treat AUD **globally**....

Global alcohol use disorder treatment market

2023 Market Value: \$700 million


2033 Projected Value: \$1,300 million

2023-2033 Growth Rate: CAGR of 6.4%

Key drivers

- Increasing rates of alcohol use and binge drinking
- Universal impact across all demographics
- Larger market than for other addictions
- Increase in treatment-seeking frequency

... and in the **U.S.** where 1.4m seek Rx help



Against this opportunity, we are developing DMX-1001...


Source: Future Market Insights, Oct 2024

For those on treatment for AUD, 60% will relapse to hazardous drinking within 6 months



Chronic relapse is driven by **lasting negative** neuroplastic changes to the addiction cycle in the brain from ongoing alcohol use.

- Existing approved medications primarily address symptoms which:
 - Modulate single target chemical imbalances in the brain.
 - Conditions aversion to alcohol in severe alcoholics.
- These approaches do not promote lasting, disease-modifying changes. This fact may explain the high relapse rates.



Financing Terms Overview: DemeRx NB Inc.



CONFIDENTIAL | 23

Key Highlights

- DemeRx NB Inc. Ownership: 100% subsidiary of DemeRx Inc.
- Raise: \$10M Convertible Note as bridge to up to \$15M Series A in 12-18 months.
- Purpose: Preparation and Phase II development, estimated at \$20M.
- Note converts into Series A Preferred stock at a 25% discount with valuation cap at \$33.75 million.
- Intellectual Property Ownership: DemeRx NB Inc. owns patents related to noribogaine (DMX-1001 molecule) research

The Offering

- Issuer:
 DemeRx NB Inc., a Delaware corporation.
- Securities Offered: \$10M Convertible Notes
- Interest:6% simple interest
- Target Close: Q4 2025

Conversion Terms

- Trigger: Automatic conversion upon Equity Financing >\$5M before maturity.
- Discount: Converts at 75% of Equity Financing price.

© 2024 DEMERX. ALL RIGHTS RESERVED







New Leadership at FDA – early meetings are scheduled with HHS, NIH before IND filing – open the door for priority review and first in class breakthrough designation.

Target Product Profile – daily tablet for Alcohol Use Disorder (off label use for other addictions).

Noribogaine will become the first line treatment for AUD, OUD and other addictions. The drug is well tolerated with few side effects.

DemeRx product will be the "metformin" for addictions.

Neuroplastogen and antidepressant mechanism of action. Its other potential health benefits (cognition enhancement, brain health, improved mood are a wonderful — not harmful — side effects.

Early engagement with payers and employer-sponsored insurance providers will be considered in terms of potentially offsetting the existing high medical cost of SUDs.

Footer





Contact



+1 786-347-3500



info@demerx.com



